CTOs on the Move

Algorithme Pharma

www.algopharm.com

 
Algorithme Pharma, Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.algopharm.com
  • 575 boul Armand-Frappier Laval (Quebec) Canada H7V 4B3
    Laval, QC CAN H7V 4B3
  • Phone: 450.973.6077

Executives

Name Title Contact Details

Similar Companies

21st Century Biochemicals

21st Century Biochemicals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AQP - Affordable Quality Pharmaceuticals

AQP - Affordable Quality Pharmaceuticals, Inc. is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Yamanouchi Pharma Ttechnologies

Yamanouchi Pharma Ttechnologies, Inc. is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GW Pharmaceuticals

GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.

Ionis Pharmaceuticals

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.